Effect picture

CNBG-VIROGIN BIOTECH(SHANGHAI)CO.,LTD. purchased about 20 acres of land in Nanxiang Town, Jiading, Shanghai.

The planned land area of the project is 13,431.500 square meters, and the total construction area of the project is 32,513 square meters. It is planned to build a 6-story inspection workshop, a 4-story production workshop and a supporting building for employees.

CNBG-VIROGIN is a joint venture between China Biotech and Fu Nuojian Biotech, and was registered and established in Shanghai in 2019.

After the establishment of the company, the company will give full play to the advantages of China Biotech and Fonova in the fields of R&D, clinical, production, sales, etc. "To achieve complementary advantages, collaborative innovation, use viral vectors as a platform, and introduce a new generation of oncolytic viruses, mRNA vaccines, and vector vaccines. And a series of products such as personalized precision diagnosis and treatment. China Bioscience plans to increase the capital of CNBG-VIROGIN, and develop mRNA vaccine products in joint ventures, improve China Biosciences' important layout in the mRNA field, and seize the technological frontier of future vaccine research and development.

The first two online lectures introduced us to the research and development process of mRNA vaccines and adenovirus vaccines, let us focus on viral vaccines. Viral vaccines refer to inactivated or attenuated viral vaccines (see the table below).

Medium is commonly used in cell culture. Chemically defined medium (CDM) means that the medium in the medium has clear ingredients, does not contain animal proteins and plant hydrolysates, and uses small molecular compounds with known structures and functions to facilitate the analysis of cell secretion product.

On September 8th, Sartorius and the biological products circle held the third lecture of the upstream part of the vaccine research and development process. This time, we invited Sun Hongliang, director of the vaccine department of the Changchun Institute of Biological Products, to share with us the selection and production process of the traditional viral vaccine research and development process. Optimization"; Zhang Peng, an expert on Sartorius media products, shared with us "Application of Chemically Qualified Media in Vaccine Production Based on Cell Culture". The wonderful content is not to be missed.

From 19:30-21:00 on the evening of September 8, we look forward to your registration and participation!

Please specify: name + research direction!

Source: Sohu

Disclaimer: Please contact us if it involves content, copyright or other issues.